Commentary

摘要

There were many interesting stud- ies presented at the 2011 San Antonio Breast Cancer Symposium (SABCS). Several trials compared single-agent hormonal therapy to dual hormonal blockade, while others compared single-agent therapy to combined therapy with another, non-hormonal biologic. Other trials identified the false negative rate of HER2/neu testing, and examined whether bisphosphonates can improve progression-free survival (PFS). Trials presented at the meeting may also lead to the eventual approval of 2 new agents: pertuzumab and T-DM1.